Real-time RT-LAMP for the Detection of SARS-CoV-2
Creative Biolabs is a leading service provider that focuses on SARS-CoV-2 drug discovery services. Currently, various platforms have been established for screening SARS-CoV-2 in different populations, and we have successfully established a series of rRT-PCR assays for identifying SARS-CoV-2 and developed a series of IVD kits for our worldwide clients.
SARS-CoV-2, a member of the coronavirus family, is an enveloped RNA virus that has been identified in many countries, such as China, Japan, Singapore, and the United States. SARS-CoV-2 occurs mainly in humans and can cause a series of severe respiratory diseases. As a result, monitoring of the SARS-CoV-2 activity plays an important role in implementing suitable virus control measures. In particular, an effective detection system for screening SARS-CoV-2 in humans should be developed and widely used for in vitro diagnosis. Currently, a number of polymerase chain reaction (PCR)-based assays have been generated, including real-time reverse transcription PCR (rRT-PCR) and reverse transcription loop-mediated isothermal amplification (RT-LAMP), for rapid detection of SARS-CoV-2 infection in various samples. Recent studies have indicated that these assays are high-throughput, efficient, and powerful tools in practical detection. However, rRT-PCR and RT-LAMP methods have also shown several drawbacks, either an intricate instrument or a manpower consuming process for the detection of SARS-CoV-2 samples. In addition, it is widely accepted that the screening results should be evaluated by multiple assays. In this condition, a single-tube real-time RT-LAMP technology has been reported to offer a fast and high specificity PCR amplification and to complement those already available.
Fig.1 Comparative sensitivity of real-time RT-LAMP, one-step RT-PCR, and real-time RT-PCR methods. (Yu, 2015)
Recently, the efficient human-to-human transmission of SARS-CoV-2 has aroused much attention all over the world, especially in China. The WHO responded quickly by encouraging in vitro diagnostics development, coordinating SARS-CoV-2 detection for virus monitor, as well as supporting drug discovery in patients. Creative Biolabs has established a single-tube real-time RT-LAMP platform for the detection of SARS-CoV-2 virus RNA.
In general, amplification of SARS-CoV-2 can be achieved by using multiple reaction primer mixes at an optimized condition. The primer mixes are derived from the published data of SARS-CoV-2 genome sequences, and the primer design is based on different types of sequence alignment software. Creative Biolabs provides in vitro diagnostic kits development services of SARS-CoV-2 by using our unique real-time RT-LAMP platform. Our goal is to promote PCR-based detection kits to clinical diagnosis for SARS-CoV-2 screening in a wide variety of human populations. We have built a team of talented and motivated scientists and technicians to pursue our commitment.
As a reliable drug discovery company, Creative Biolabs is committed and proud to be part of this rewarding challenge by offering its support to the SARS-CoV-2 IVD kits development services and pre-clinical drug discovery for our clients. We are proud to partner with you on the journey of bringing novel candidate drugs to SARS-CoV-2 infection disease therapy in the clinic. If you are interested in our services, please contact us for more details.
Welcome! For price inquiries, please feel free to contact us through the form on the left side. We will get back to you as soon as possible.